NCT01425398

A Trial to Evaluate the Effect of Rosuvastatin on Inflammation in Patients Undergoing Isolated Cardiac Valve Surgery

A Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Effect of Rosuvastatin on Inflammation in Patients Undergoing Isolated Cardiac Valve Surgery

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 170 (actual)
• Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

High-dose statin therapy around the time of surgery, decreases inflammation in patients undergoing cardiac valve surgery, and thereby improves clinical outcomes.

Conditions

• Valvular Cardiac Surgery

Interventions

Type	Name	Description
DRUG	Rosuvastatin	Rosuvastatin 40 mg PO qd x 5 days before surgery and then from post-op day 0 to 5.
DRUG	Placebo	Placebo 1 tab qd x 5d before operation and then from post-op day 0 to 5.

Timeline

• Start date: 2011-11-01
• Primary completion: 2013-12-01
• Completion: 2013-12-01
• First posted: 2011-08-30
• Last updated: 2021-10-21

Locations

1 site across 1 country: Canada